Treatment failure and hospital readmissions in severe COPD exacerbations treated with azithromycin versus placebo - A post-hoc analysis of the BACE randomized controlled trial
Vermeersch, K.; Laboratory of Respiratory Diseases, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Herestraat 49, OandNI, box 706, Leuven, B-3000, Belgium, Department of Respiratory Diseases, University Hospitals Leuven, Leuven, B-3000, Belgium
Gyselinck, I.; Laboratory of Respiratory Diseases, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Herestraat 49, OandNI, box 706, Leuven, B-3000, Belgium
Cardinaels, N.; Laboratory of Respiratory Diseases, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Herestraat 49, OandNI, box 706, Leuven, B-3000, Belgium
Gabrovska, M.; Department of Pneumology, Centre Hospitalier Universitaire Saint-Pierre, Université Libre de Bruxelles, Brussels, B-1000, Belgium
Aumann, J.; Department of Pneumology, Jessa Ziekenhuis, Hasselt, B-3500, Belgium
Demedts, I. K.; Department of Respiratory Medicine, AZ Delta Roeselare-Menen, Roeselare, B-8800, Belgium
Corhay, Jean-Louis ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Marchand, E.; Department of Pneumology, CHU-UCL-Namur, Site Mont-Godinne, Yvoir, B-5530, Belgium, Faculty of Medicine, NARILIS, Laboratory of Respiratory Physiology, University of Namur, Namur, B-5000, Belgium
Slabbynck, H.; Department of Respiratory Medicine, ZNA Middelheim, Antwerpen, B-2020, Belgium
Haenebalcke, C.; Department of Pneumology, AZ Sint-Jan, Brugge-Oostende, B-8000, Belgium
Vermeersch, S.; Department of Respiratory Medicine, Ghent University Hospital, Ghent, B-9000, Belgium
Verleden, G. M.; Laboratory of Respiratory Diseases, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Herestraat 49, OandNI, box 706, Leuven, B-3000, Belgium, Department of Respiratory Diseases, University Hospitals Leuven, Leuven, B-3000, Belgium
Troosters, T.; Laboratory of Respiratory Diseases, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Herestraat 49, OandNI, box 706, Leuven, B-3000, Belgium, Department of Rehabilitation Sciences, Faculty of Kinesiology and Rehabilitation Sciences, KU Leuven, Leuven, Belgium
Ninane, V.; Department of Pneumology, Centre Hospitalier Universitaire Saint-Pierre, Université Libre de Bruxelles, Brussels, B-1000, Belgium
Brusselle, G. G.; Department of Respiratory Medicine, Ghent University Hospital, Ghent, B-9000, Belgium
Janssens, W.; Laboratory of Respiratory Diseases, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Herestraat 49, OandNI, box 706, Leuven, B-3000, Belgium, Department of Respiratory Diseases, University Hospitals Leuven, Leuven, B-3000, Belgium
Ninane, V.
Aumann, J.; Department of Pneumology, Jessa Ziekenhuis, Hasselt, B-3500, Belgium
Demedts, I. K.; Department of Respiratory Medicine, AZ Delta Roeselare-Menen, Roeselare, B-8800, Belgium
Slabbynck, H.; Department of Respiratory Medicine, ZNA Middelheim, Antwerpen, B-2020, Belgium
Marchand, E.
Haenebalcke, C.; Department of Pneumology, AZ Sint-Jan, Brugge-Oostende, B-8000, Belgium
Treatment failure and hospital readmissions in severe COPD exacerbations treated with azithromycin versus placebo - A post-hoc analysis of the BACE randomized controlled trial
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;157(5):1418-22.
Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obs Pulmon Dis. 2009;4:245-51.
Wedzicha JA, Donaldson GC. Natural history of successive COPD exacerbations. Thorax. 2012;67(11):935-6.
Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD, 2018 report. 2018. Available from: http://goldcopd.org
Halpin DMG, Miravitlles M, Metzdorf N, Celli B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J COPD. 2017;12:2891-908.
Vermeersch K, Gabrovska M, Aumann J, et al. Azithromycin during acute COPD exacerbations requiring hospitalization (BACE): a multicentre, randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2019; In Press.
Rauch G, Kieser M, Binder H, Bayes-Genis A, Jahn-Eimermacher A. Time-to-first-event versus recurrent-event analysis: points to consider for selecting a meaningful analysis strategy in clinical trials with composite endpoints. Clin Res Cardiol. 2018;107(5):437-43.
Vermeersch K, Gabrovska M, Deslypere G, et al. The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. Int J COPD. 2016;11(1):687-96.
Müller B, Peri G, Doni A, et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol. 2002;72(4):643-9.
Rennard SI, Farmer SG. Exacerbations and progression of disease in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1(2):88-92.
Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014;189(12):1503-8.
Krishnan JK, Voelker H, Connett JE, et al. Effect of daily azithromycin therapy and adherence on readmission risk in COPD. Eur Respir J. 2019;53(3). https://doi.org/10.1183/13993003.01377-2018.
Pomares X, Montón C, Bullich M, et al. Clinical and safety outcomes of long-term azithromycin therapy in severe COPD beyond the first year of treatment. Chest. 2018;153(5):1125-33.
Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J. 2012;40(1):17-27.
Irani AP, Hicks LS. Reducing the readmission burden of COPD: a focused review of recent interventions. Curr Emerg Hosp Med Rep. 2014;2(3):172-81.
Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA - J Am Med Assoc. 2010;303(20):2035-42.
Brightling CE. Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10:S214-9.
Bafadhel M, Clark TW, Reid C, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest. 2011;139(6):1410-8.
Prins HJ, Duijkers R, van der Valk P, et al. CRP-guided antibiotic treatment in acute exacerbations of COPD admitted to hospital. Eur Respir J. 2019;53(5). https://doi.org/10.1183/13993003.02014-2018.
Stolz D, Christ-Crain M, Gencay MM, et al. Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection. Swiss Med Wkly. 2006;136(27-28):434-40.
Daniels JMA, Snijders D, De Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(2):150-7.
Bafadhel M, Mckenna S, Terry S, et al. Blood Eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(1):48-55.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.